Fig. 2: Clinical manifestations change over time.

The clinical manifestation change from baseline in the Low-dose interleukin-2 (LD-IL-2) group(n = 26) and placebo group(n = 30) was shown and compared using a T-test with two-sided P values(degrees of freedom = 54, confidence intervals = 95%). No adjustments made for multiple comparisons. No replication. The treatment period is 0 to 12 weeks, and the follow-up period is 12 to 24 weeks. a The changes in the number of oral ulcers. Week 4 t = −2.59, P = 0.012. Week8 t = −4.40, P < 0.001. Week 12 t = −3.34, P = 0.002. b The changes in the number of genital ulcers. Week 4 t = −3.29, P = 0.002. Week 12 t = −2.45, P = 0.018. Week 24 t = −12.06, P < 0.001. c The changes in Behcet’s disease current activity form scores(BDCAF). Week 12 t = −3.00, P = 0.004. d The changes in visual-analog scale scores(VAS). Week 12 t = −2.22, P = 0.030. Data points represent mean values, and error bars indicate the standard error of the mean (SEM). *p < 0.05(LD-IL-2 vs. placebo). Source data are provided as a Source Data file.